(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Photos: Hundreds Gather at Bondi Beach After Deadly Attack - 2Artemis moon mission breaks record for distance from Earth
- 3Overseeing Individual budgets Successfully
- 44 Electric Vehicle Brands: Execution, Unwavering quality, and Development
- 5Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- Nepal’s youngest premier sworn in after releasing new rap song about unity
- Mossad unveils network of Hamas terror infrastructure across Europe
- UAE recalls some Nestle infant formula products, Qatar warns consumers
- Day to day Temporary Positions That Compensate Fairly in the US
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- The best ice packs for coolers of 2026, tested and reviewed
- The Best 15 Applications for Efficiency and Association
- 'A perfect storm': Airlines cut flights and increase airfares as jet fuel price spikes
- Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
